Quantum Biosystems, an Osaka, Japan-based company that applies quantum mechanics to the development of innovative single-molecule DNA sequencers, raised 2.4bn yen in Series B funding.
Backers included new investors Innovation Network Corporation of Japan(INCJ) and Mitsubishi UFJ Capital(MUCAP), and three existing investors JAFCO, UTEC and Mizuho Capital.
The company intends to use the funds to accelerate DNA/RNA sequencer development.
Quantum is led by Toshihiko Honkura, co-founder, President and Chief Executive Officer.
FinSMEs
09/02/2015